| |
Comparison |
HR |
95% CI low |
ln(HR) |
SE |
p value |
| Outcome |
Dabrafenibvs |
| PFS |
Vemurafenib |
0.97 |
0.60–1.57 |
-0.03 |
0.24 |
0.91 |
| Ipilimumab+DTIC |
0.49 |
0.30–0.79 |
-0.71 |
0.25 |
0.003 |
| Temozolomide |
0.40 |
0.25–0.64 |
-0.92 |
0.24 |
0.0001 |
| OS |
Vemurafenib |
0.86 |
0.32–2.29 |
-0.15 |
0.50 |
0.76 |
| Ipilimumab+DTIC |
0.76 |
0.29–2.03 |
-0.27 |
0.50 |
0.59 |
| Temozolomide |
0.55 |
0.21–1.45 |
-0.60 |
0.49 |
0.23 |
| |
Trametinibvs |
| PFS |
Vemurafenib |
1.16 |
0.71–1.88 |
0.15 |
0.25 |
0.55 |
| Ipilimumab+DTIC |
0.58 |
0.35–0.95 |
-0.54 |
0.25 |
0.03 |
| Temozolomide |
0.48 |
0.30–0.77 |
-0.74 |
0.24 |
0.00 |
| Dabrafenib |
1.19 |
0.63–2.23 |
0.17 |
0.32 |
0.59 |
| OS |
Vemurafenib |
0.88 |
0.45–1.69 |
-0.13 |
0.33 |
0.69 |
| Ipilimumab+DTIC |
0.78 |
0.40–1.50 |
-0.25 |
0.33 |
0.45 |
| Temozolomide |
0.56 |
0.29–1.07 |
-0.58 |
0.33 |
0.08 |
| Dabrafenib |
1.02 |
0.32–3.20 |
0.02 |
0.58 |
0.98
|
| |
Comparison |
RR |
95% CI low |
ln(RR) |
SE |
pvalue |
| |
Dabrafenibvs |
| ORR |
Vemurafenib |
0.37 |
0.21–0.67 |
-0.99 |
0.30 |
0.001 |
| Ipilimumab+DTIC |
1.68 |
0.87–3.23 |
0.52 |
0.34 |
0.12 |
| Temozolomide |
1.62 |
0.89–2.94 |
0.48 |
0.30 |
0.12 |
| CR |
Vemurafenib |
0.30 |
0.07–1.35 |
-1.20 |
0.75 |
0.12 |
| Ipilimumab+DTIC |
0.71 |
0.10–5.19 |
-0.34 |
1.01 |
0.74 |
| Temozolomide |
0.71 |
0.15–3.50 |
-0.34 |
0.81 |
0.68 |
| |
Trametinibvs |
| ORR |
Vemurafenib |
0.32 |
0.13–0.74 |
-1.15 |
0.43 |
0.01 |
| Ipilimumab+DTIC |
1.42 |
0.58–3.51 |
0.35 |
0.46 |
0.44 |
| Temozolomide |
1.37 |
0.58–3.25 |
0.31 |
0.44 |
0.47 |
| Dabrafenib |
0.85 |
0.35–2.08 |
-0.16 |
0.46 |
0.72 |
| CR |
Vemurafenib |
0.80 |
0.04–18.51 |
-0.22 |
1.60 |
0.89 |
| Ipilimumab+DTIC |
1.90 |
0.06–57.02 |
0.64 |
1.75 |
0.71 |
| Temozolomide |
1.91 |
0.08–46.00 |
0.65 |
1.62 |
0.69 |
| Dabrafenib |
2.68 |
0.12–61.25 |
0.99 |
1.60 |
0.54 |
| DTIC: Dacarbazine; HR: Hazard Ratio; ORR: Overall Response Rate; OS: Overall Survival; PFS: Progression-Free Survival; RR: Risk Ratio;SE: Standard Error
aFor PFS, June 2012 data for BREAK-3, October 2011 data for METRIC, and February 2012 data for BRIM-3 were used; for OS, December 2012 data for BREAK-3, October 2011 data for METRIC, and February 2012 data for BRIM-3, all adjusted for crossover were used. HRs and RRs<1 indicate a lower risk/incidence in favor of dabrafenib or trametinib versus the comparator. |
|
